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Background: Rurality and distance from cancer treatment centres have been shown to negatively impact cancer outcomes, but
the mechanisms remain obscure.
Methods: We analysed the impact of travel time to key healthcare facilities and mainland/island residency on the cancer
diagnostic pathway (treatment within 62 days of referral, and within 31 days of diagnosis) and 1-year mortality using a data-linkage
study with 12 339 patients.
Results: After controlling for important confounders, mainland patients with more than 60min of travelling time to their cancer
treatment centre ((OR 1.42; 95% CI 1.25–1.61) and island dwellers (OR 1.32; 95% CI 1.09–1.59) were more likely to commence cancer
treatment within 62 days of general practitioner (GP) referral and within 31 days of their cancer diagnosis compared with those living
within 15min. Island-dweller patients were more likely to have their diagnosis and treatment started on the same or next day (OR 1.72;
95% CI 1.31–2.25). Increased travelling time to a cancer treatment centre was associated with increased mortality to 1 year (30–59min
(HR 1.21; 95% CI 1.05–1.41), 460min (HR 1.18; 95% CI 1.03–1.36), island dweller (HR 1.17; 95% CI 0.97–1.41).
Conclusions: Island dwelling and greater mainland travel burden was associated with more rapid cancer diagnosis and treatment
following GP referral even after adjustment for advanced disease; however, these patients also experienced a survival
disadvantage compared with those living nearer. Cancer services may need to be better configured to suit the different needs of
dispersed populations.
Short diagnostic and treatment intervals are perceived as critical to
optimal cancer outcomes. This has been reflected within the past
10 years in the UK National Health Service (NHS) through the
development of referral guidelines and strict targets for the
timeliness of referral, investigation and management of suspected
and confirmed cancer. This has corresponded to the centralisation
of cancer services at high-volume hospitals, and the formation of
cancer networks (Department of Health England, 2007; The
Scottish Government, 2008; NHS Scotland, 2016; NICE, 2016).
Primary care general practitioners (GPs) continue to be gate-
keepers to secondary care within the UK NHS and represent the
first of three discrete types of healthcare facility that are key
touchpoints on the cancer care pathway in the United Kingdom:
GP practice, cancer diagnosis centre and cancer treatment centre.
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Rurality and the burden of travel (distance and/or time) from
patients’ residence to key healthcare facilities have been associated
with negative impacts on cancer outcomes in studies from the
United Kingdom and elsewhere (Campbell et al, 2000; O’Brien
et al, 2000; Coory et al, 2006; Underhill et al, 2006; Westeel et al,
2007; Jones et al, 2008a; Coughlin et al, 2008; Pozet et al, 2008).
Although this association is now well described, the underlying
mechanisms remain obscure. It could be that increased burden of
travel restricts access to key healthcare facilities, for which some
evidence already exists (Campbell et al, 2002; Jones et al, 2008b;
Lin et al, 2015; Murage et al, 2016). People with colorectal cancer
living further away from cancer centres are less likely to receive
chemotherapy or radiotherapy compared with those living closer
(Campbell et al, 2002; Lin et al, 2015). Lung cancer patients living
further from a hospital were less likely to receive surgery, and both
lung and rectal cancer patients were less likely to receive
chemotherapy if they lived distant from these services (Jones
et al, 2008b). This could lead, in turn, to under or later utilisation
of diagnostic and treatment resources by more remote populations.
However, if restricted access were a truly impactful mechanism, it
would likely be reflected by longer delays to be diagnosed with and
treated for cancer for those patients living more remotely. Longer
delays ultimately could result in later-stage diagnosis and later
treatment with subsequent implications for the likelihood of
curative treatment and prolonged disease-free survival. Such a
mechanism could be consistent with evidence reported from across
a range of other health conditions, where greater distance and/or
greater travel time have been linked to negative impacts on the
process of care, particularly reduced engagement with preventive
care, delayed diagnosis and treatment and poorer health outcomes
(Chan et al, 2006; Probst et al, 2007; Baird et al, 2008; Baldwin
et al, 2008; Onega et al, 2008; Ahamad, 2011; Chou et al, 2014).
However, the impact of burden of travel on the process of cancer
care, particularly the potential for delayed diagnosis and treatment
in the United Kingdom, has been difficult to explore until now.
Data-linkage techniques are improving all the time and research
opportunities are burgeoning (Higgs, 2009). Greater opportunities
now exist to link evolving Geographic Information Systems (GIS)
to improved routine administrative healthcare data and increas-
ingly comprehensive specialist disease registries. The resultant
linked data sets will enable greater in-depth study of the complex
relationships between geography, service delivery, processes of care
and health outcomes in real-life data (Higgs, 2009). This is
certainly the case in cancer, and GIS are becoming prominent in
cancer epidemiological studies (Hyndman and Holman, 2000;
Najafabadi and Pourhassan, 2001; Nattinger et al, 2001; Jones et al,
2008b; Peipins et al, 2013). With respect to the process of cancer
diagnosis and treatment, there are now opportunities to explore in
greater detail than before whether burden of travel can impact the
cancer care pathway rather than just cancer outcomes.
The Northeast Scotland health region (comprising the health
boards of Grampian, Orkney and the Shetland Isles) has a single
specialist cancer centre providing care to a geographically diverse
population. Urban, suburban, rural and island communities are all
represented. We have linked whole population health records across
the cancer care pathway and identified a cohort of 12 339 people
diagnosed with one of the UK eight commonest cancers between
2007 and 2014. In this paper we present a unique exploration of how
burden of travel might influence both process and outcomes in
cancer care in both mainland and island communities.
MATERIALS AND METHODS
Study design and population. In this data-linkage study we
created a population-based cohort, Northeast and Aberdeen
Scottish Cancer and Residence (NASCAR). The NASCAR cohort
captured all patients with one of eight common cancers for a
defined geographical area (approximate population¼ 587 820)
comprising a single health region and two island communities
served by 112 GP practices, three cancer diagnosis centres
(comprising two hospitals and the screening service) and one
cancer treatment centre service on the UK mainland. Linkage and
creation of NASCAR was approved by a privacy advisory
committee and managed in Grampian Data Safe Haven
(University of Aberdeen, 2016).
Data sources. The primary data source for this study was the
Health Authority (NHS Grampian) Cancer Care Pathway (CCPd)
database, an electronic clinical database maintained since 2006.
The CCPd collects information from several sources to form a
complete record of secondary care activity in individual cancer
cases, from receipt of GP referral, for all people diagnosed with
cancer. The CCPd records information about referral, diagnosis,
subsequent investigations and secondary care appointments,
intrasecondary care referrals, investigations, hospital admissions
and discharges, operations and treatment. The accuracy of the
CCPd has been validated (Murchie et al, 2013). Data were
extracted from the CCPd for individuals diagnosed with eight
common cancers (colorectal, lung, breast, prostate, melanoma,
oesophagogastric, cervical and ovarian) from 2007 to 2014. This
provided the patient population for the NASCAR cohort.
Using residential postcodes (geo-reference for postcode cen-
troid), we assigned The Scottish Index of Multiple Deprivation
(SIMD) and the Scottish Government Urban-Rural Classification
to the CCPd cohort data set. The SIMD identifies small area
concentrations of multiple deprivations across all of Scotland in a
consistent way. The indicators that make up the SIMD are chosen
because they are measures of deprivation regardless of where a
person lives, and therefore the issue for rural areas is that poverty
and deprivation are more spatially dispersed than in urban areas.
The SIMD is measured across seven domains: current income,
employment, health, education, skills and training, housing,
geographic access to services (including drive and public transport
times) and unemployment counts are averaged to take account of
seasonal fluctuations in employment patterns (seasonality tends to
affect rural areas more than urban areas((The Scottish
Government, 2016). The Scottish Government Urban-Rural
Classification provides a standard definition of rural areas in
Scotland. This information was then used to assign each Scottish
postcode to a two-fold category of urban or rural (The Scottish
Government, 2014, 2016). The SIMD data come from a variety of
different sources and data providers quality assure data before
providing them to the Office of the Chief Statistician and
Performance (OCSP). The OCSP also carries out further checks
to ensure the data are fit for purpose.
The Scottish Cancer Registry records information on cancer
type, date of diagnosis, stage at diagnosis, treatment received and
date. Approximately 47 000 registrations are made annually in
Scotland (Brewster et al, 1994, 2002). This registry provided
information on stage at diagnosis and treatment received and
allowed cross-reference with the primary data source for variables
such as cancer type and date of diagnosis. Data quality of the
Scottish Cancer Registry is monitored using routine indicators,
computer validations and ad hoc studies of data accuracy and
completeness of ascertainment (Brewster et al, 1994, 2002;
Information Services Division, 2017a,b).
Hospital episode data record all inpatient and day cases
discharged from Scottish acute hospitals (Information Services
Division, 2012). The data quality is regularly assessed and validated
(Information Services Division, 2012). A weighted Charlson
comorbidity score was calculated for each patient based on their
hospital episode data (Charlson et al, 1987). The score was
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calculated from principal and supplementary diagnostic ICD 10
codes from hospital attendances and admissions for 10 years before
cancer diagnosis for each patient and excluded cancer or metastatic
cancer. This allowed for adjustment in the statistical analysis for
comorbidity.
Death registry data from the National Records of Scotland
(NRS) records information relating to all deaths, including
principal and secondary causes of death. This information was
used to determine if the principal cause of death was cancer. The
data are of a high standard and are the most reliable death data set
available in Scotland. Automatic quality checks are carried out at
the point of entry and when the information is passed into the
National Records of Scotland Vital Events statistical database
(National Records of Scotland, 2017).
Postcodes for residential, GP practice, cancer diagnosis centre
and cancer treatment centre were available for each individual
from the CCPd. To model fastest travel times to the three key
healthcare facilities used during each individuals cancer diagnostic
pathway, road networks and flight routes (for island patients) from
place of residence were calculated using the Network Analyst
extension in ArcGIS V10.2 (ESRI: Environmental Systems
Research Institute, Redlands, CA, USA).
Preliminary data by our research group showed that 67% of
people diagnosed with the cancers of interest in the study area
between 2006 and 2013 were treated within 62 days. Assuming a
differential of 2% between each access groups (69%, 67% and 65%)
we would have 80% power to detect that difference with a sample
size of 2662 in each group (assuming equal numbers), and 90%
power with 3493 in each group. We were able to meet this
requirement.
Data linkage. Data linkage enables population follow-up without
formal patient recruitment that minimises selection bias. Informa-
tion Services Division (ISD) Scotland performed the linkages using
the community health index (CHI), a unique identifier for all
residents in Scotland. This allows all the records from multiple data
sets from primary care, secondary care and specialist disease
registries to be linked (ScottisH Informatics Project (SHIP), 2003).
Data extraction and linkage were carried out by ISD Scotland and
Grampian Data Safe Haven (DaSH). Data were pseudoanonymised
before release to our research group for analysis in the secure
virtual research environment in DaSH.
The linkage created a novel longitudinal data set, NASCAR, for
a defined geographical population.
The NASCAR-linked data set contained information on mode
and date of diagnosis, date of presentation, date of GP referral
(where applicable), date of first hospital assessment, date of
subsequent hospital investigations, date of treatment decision and
the nature and date of definitive treatment. This information
enabled calculation of defined individual diagnostic and treatment
intervals (Weller et al, 2012).
Exposure: burden of travel expressed as travel times. Travel
times from place of residence to the three key healthcare facilities
were defined as follows: travelling time to GP: o5.0min for
mainland residents, 5.0–9.9min for mainland residents, 10.0–
14.9min for mainland residents,415.0min for mainland residents
and a category for all island residents; travelling time to centre of
diagnosis and cancer centre: o15.0min for mainland residents,
15.0–29.9min for mainland residents, 30.0–59.9min for mainland
residents, 460.0min for mainland residents and a category for all
island residents.
In the analysis of travelling time to GP, we could have included
the island patients by time, but for comparability with the other
analyses we left this as a separate category. Of the island patients,
31.1% had a travelling time of 410min compared with 16.3% of
patients residing on the mainland. Having a distinct island
category aimed to capture the complexity of additional factors
that could influence accessibility. The reference category for GP
practice was o5.0min for mainland residents and for cancer
diagnosis centre and cancer treatment centre was o15.0min for
mainland residents.
Outcomes. The main outcome measure was treatment started
within 62 days after the GP referral date (yes or no). This
categorisation was based on national government targets to receive
treatment within 62 days from the date of urgent referral with
suspicion of cancer. This includes referrals from national cancer
screening programmes (Department of Health England, 2007; The
Scottish Government, 2008).
We included the variable ‘first cancer treatment started within
31 days after diagnosis date’ as a secondary outcome to examine
delay in more detail. This was based on national government target
of 31 days from decision to treat until first treatment for all new
cancer diagnoses, irrespective of the route of referral into the
system (The Scottish Government, 2008). The impact of travelling
time on treatment occurring on the same or next day as diagnosis
was also investigated.
One-year mortality was chosen as it seems plausible that this
would be most sensitive to differential geographic access to cancer
diagnostic and treatment facilities. Arguably, focussing on longer-
term mortality could be more susceptible to confounding by, for
example, healthier rural lifestyles or lesser deprivation. Follow-up
was from the date of GP referral to 5 December 2014. This cutoff
date meant we were unable to include patients referred after 5
December 2013 (n¼ 1198) in the mortality analysis. Those not
registered as dead during follow-up were assumed to be still alive.
Mortality was measured from date of GP referral rather than date of
diagnosis or first treatment to overcome lead-time bias. A sensitivity
analysis was conducted calculating mortality from date of diagnosis.
Covariates of interest. We reported age, sex, level of deprivation
(SIMD quintiles), rurality (based on the Scottish two-fold urban
rural classification ((urban/rural), Charlson score, urgency/referral
status (urgent suspected cancer, urgent, routine, screening,
emergency and other), cancer type (breast, ovarian, cervical,
prostate, melanoma, lung, oesophagogastric or colorectal), diag-
nostic procedure (imaging, endoscopy/endoscopic biopsy, opera-
tive biopsy/surgery, or other) and main or first treatment type
(surgery, chemotherapy/radiotherapy or other).
Sensitivity analyses were carried out to explore potential bias
from differences in the diagnostic process for cancer type
(melanoma and prostate) and all patients who were diagnosed
through a screening services. Both melanoma and prostate tend to
have less aggressive treatment than the other cancer types, and this
could have an effect on the diagnosis and treatment targets in the
diagnostic pathway and also on mortality outcomes.
Information on stage of cancer provided by the Scottish Cancer
Registry was not complete, largely because stage was not collected
for some of the included cancer sites during the time frame of this
study. Metastatic cancer information taken from hospital episode
data was used as a proxy for stage of cancer, as has been
used previously (Parks et al, 2004). We carried out sensitivity
analyses on patients who had stage recorded in the Scottish Cancer
Registry.
Previous work published by our research group excluded
tumour stage as a predictor variable from multivariate survival
models (Murchie et al, 2015). The rationale behind this was that if
time between presentation and treatment is an important factor for
mortality, then its effects would be via more advanced disease
stage. We have performed additional sensitivity analysis for
mortality to 1 year without adjustment for either metastatic
disease or stage.
Analysis. Statistical analyses were performed using SPSS V.23
(IBM, Armonk, NY, USA) and SAS V9.3 (SAS Institute, Cary,
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NC, USA). The data set was cleaned and missing data analysis was
performed. In all, 1363 (12 339 of 13 702) (9.9%) had X1 of the
case-mix adjustment variables missing, and exploratory analysis was
performed to assess missing data patterns. To assess whether missing
case-mix variables would affect the results, we performed missing
data imputation using the Markov chain Monte Carlo method with
5 iterations. The adjusted odds ratios (ORs) with 95% confidence
interval (CI) for outcomes restricted to the cases with complete case-
mix information were more conservative than the results for all cases
with imputation of missing data. All estimates were therefore
focussed on analysis of cases where all key data items were complete.
Baseline characteristics (at time of referral) were summarised.
To explore the association for each of the three healthcare
facilities between the binary outcomes (treatment by 62 days post
referral, treatment by 31 days from diagnosis and treatment and
diagnosis on the same or next day) with travelling time we used
logistic regression to estimate the OR and 95% CIs. We present
unadjusted and adjusted models. Adjusted models included age in
years at the time of referral, gender, urban/rural, deprivation (based
on postcode), referral urgency/referral status, cancer type, diagnostic
procedure type, Charlson comorbidity index (CCI score), first
treatment type and diagnosis of metastatic cancer as a marker of
cancer stage. Selection of adjustment factors was based on clinical
importance and statistical significance. We included the Scottish
two-fold urban rural classification in the adjusted model in addition
to travelling time as these represent different measures. An urban
residence could have a longer travelling time than a rural residence
because of the location of one of the key healthcare components.
The Kaplan–Meier curves were plotted for both cumulative
observed mortality and cumulative cancer-specific mortality at 1
year from the date of GP referral for travelling time to cancer
treatment centre. We used Cox proportional hazards model with
adjustment for estimating the hazard of mortality within 1 year of
GP referral date and calculating hazard ratios (HRs) in relation to
travelling times to the three healthcare components.
Patient involvement. This is an unconsented data linkage study.
As part of the Administrative Data Research Centre (ADRC)
Scotland and Farr Institute Scotland, large public engagement
exercises have been conducted to discuss the use of health and
administrative data in research. The input from these events has
shaped the types of data for linkage, the approach to linkages and
the governance around data linkage. This project was reviewed by a
Privacy and Public Benefit panel (PPBP) that includes lay
representative input. No patients were involved in setting the
research question or the outcome measures, nor were they involved
in developing plans for design or implementation of the study. No
patients advised on the interpretation or writing up of results. As
part of the dissemination of the results of the research we plan to
prepare a #Datasaveslives case study that will be made available via
the Farr Institute for Health Informatics Engagement Team.
Ethical approval. Ethical approval was not needed. Privacy
Advisory Committee (PAC) was obtained from Information Services
Division (ISD) of NHS National Services Scotland for accessing and
linking the data sources (Reference number 0942/14).
RESULTS
All categorisations stated in the results refer to travelling times for
patients residing on the mainland. Island patients were a distinct
category regardless of lengths of travelling times. The reference
category for all analyses refers to the category closest to the key
healthcare facilities.
A total of 12 339 patients with one of eight common cancers
were included in the study. Figure 1 presents the flow diagram
detailing the numbers of individuals at each stage of the data
linkage and analysis. The median (IQR) age of patients was 69 (59–
77) years. Table 1 shows patient and care pathway characteristics
for the cohort at the time of GP referral. Over half the cohort was
female (56.1%) and over 80% were in the three least deprived
quintiles. Of the cohort, 65.4% had their place of residence in an
urban area; 25.9% of the cohort were referred as urgent suspected
cancer (equivalent to 2-week wait referrals in England) with an
additional 28.0% as urgent. Screening services identified 15.2% and
emergency admissions 13.1% of the cohort.
The cancer types with the highest percentages were breast
(30.6%), colorectal (22.5%), lung (14.1%) and prostate (1.3%). In
addition, 69.2% of patients scored zero on the CCI at the time of
cancer diagnosis.
A majority of patients were diagnosed by endoscopy or
endoscopic biopsy (46.8%), operative biopsy or surgery (31.4%) or
imaging (17.1%). Surgery (51.0%) was the main first treatment type.
Treatment within 62 days of referral. Table 2 presents the results
of the adjusted logistic regression analysis to explore the
association of treatment within 62 days of GP referral and
travelling time from GP practice; cancer diagnosis centre; and
cancer treatment centre.
Patients who had between 5–9.9 and 10–14.9min of travelling
time from their residence to their GP practice were less likely to
have treatment started within 62 days of referral compared with
those living o5min from their GP practice. There were no
associations between travelling time from home to centre of
diagnosis and treatment within 62 days of referral in the fully
adjusted regression model.
Patients who had 460min of travelling time from their
residence to their cancer centre were more likely to receive
treatment within 62 days of their GP referral. This was also seen for
patients who resided on an island community.
Sensitivity analysis excluding melanoma and prostate cancer
patients and patients picked up through screening (Supplementary
Table A) and analysis on only those with a staging variable
(Supplementary Table B) showed a similar pattern of results.
Treatment within 31 days of diagnosis. Table 2 presents the
results of the adjusted logistic regression analysis to explore the
association of treatment within 31 days of diagnosis date and
travelling time from GP practice; cancer diagnosis centre; and
cancer treatment centre. Travelling time to GP practice and cancer
diagnosis centre for mainland patients did not show any
differences in the proportion treated within 31 days from
diagnosis. However, those living on islands showed an increased
likelihood of treatment within 31 days from diagnosis compared
with those living closer.
Patients who had460min of travelling time from their residence
to their cancer treatment centre or those residing on the islands were
more likely to start treatment within 31 days of their diagnosis date
compared with those living within 15min. Sensitivity analysis
excluding melanoma and prostate cancer patients and patients
picked up through screening (Supplementary Table A) and analysis
on only those with a staging variable (Supplementary Table B)
showed the same pattern of results.
Table 2 shows that island patients were much more likely to
receive treatment the same or next day after diagnosis. Differing
travelling times showed no effect here. The same pattern of results
was seen for the sensitivity analysis excluding melanoma and
prostate cancer patients and patients picked up through screening
(Supplementary Table A) and analysis on only those with a staging
variable (Supplementary Table B).
Mortality to 1 year as the outcome. A total of 11 141 patients had
a GP referral date before 5 December 2013 (the cutoff date for
complete 1-year follow-up) and were therefore eligible for
inclusion in the mortality analysis.
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Figure 2 presents the Kaplan–Meier curve for cumulative
observed mortality for 1 year following GP referral. Those residing
430min from their cancer treatment centre and those on an
island had a lower survival distribution compared with those
residing o15min from their cancer treatment centre.
Table 3 shows the unadjusted and adjusted HRs to explore the
association between travelling time from GP practice; cancer
diagnosis centre; and cancer treatment centre and mortality to 1
year from all causes of death. Patients who resided 430min from
their home to their cancer treatment centre were less likely to
survive to 1 year. Living on an island community showed a similar
association, although the 95% CI did not reach significance.
Sensitivity analysis excluding melanoma and prostate cancer
patients showed a similar pattern of results (Supplementary
Table C). Analysis on only those with a staging variable
(Supplementary Table D) and analysis excluding both metastatic
cancer and stage (Supplementary Table E) did not alter the
significance of the results for mortality to 1 year.
A sensitivity analysis was conducted measuring mortality from
date of diagnosis rather than GP referral (Supplementary Table F).
Date of diagnosis reduced the significance of the results seen with
date of GP referral for travelling time to cancer treatment centre
for all mortality.
Figure 3 presents the Kaplan–Meier curve for cumulative
cancer-specific mortality for 1 year following GP referral. Residents
with 430min of travelling time and island dwellers had a lower
survival distribution compared with those living o15min from
their cancer treatment centre.
Table 3 also shows that patients who resided430min from their
home to their cancer treatment centre were more likely to die from
cancer at 1 year. Sensitivity analysis excluding melanoma and
prostate cancer patients (Supplementary Table C) and on only those
with a staging variable (Supplementary Table D) showed a similar
pattern of results, although there was a reduction in the significance.
Cancer-specific mortality to 1 year from date of diagnosis reduced
the significance of the results seen with date of GP referral for
travelling time to cancer treatment centre (Supplementary Table F).
DISCUSSION
Principal findings. This is the first study to our knowledge
exploring the impact of burden of travel on the cancer diagnostic
process. We have shown that those with an increased burden of
travel to key healthcare components (GP practice, cancer diagnosis
Extracted from CCPd (n = 1 4509)
Excluded (n = 23)
Resident out with study region (n =20)
Identical duplicate entry (n =3)
Outcomes: treatment within 62 days after GP 
referral; treatment started within 31 days after 
diagnosis date; diagnosis and treatment 
started on same or next day.
Analysed (n =1 2339)
Excluded from analysis because of missing 
data (n =1363) 
Scottish cancer registry
(n =1 2812)
Hospital episode data
(n =1 3909)
Outcome: survival to 1 year; cancer-
specific survival to 1 year. 
Analysed (n =1 1141)
Excluded from analysis because of GP 
referral date after 5 December 2013
(n =1198)
Linkage
Analysis
CCPd data set for linkage (n =1 4486)
GIS measures
(n =1 2812)
NRS
(n =6171)
NASCAR data set (n =1 4486)
Excluded (n =723)
Recurrent cancer (n =593)
Duplicate entry for same cancer type
within 1-year period (n =130)
NASCAR data set (n =1 3702)
♦
♦
♦
♦
♦
♦
Figure 1. Flow diagram of study population. CCPd¼Cancer Care Pathway Database (NHS Grampian); GIS¼Geographic Information Systems;
NASCAR¼Northeast and Aberdeen Scottish Cancer and Residence; NRS¼National Records of Scotland.
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centre and cancer treatment centre) appear to be diagnosed and
receive primary treatment more quickly when they develop
common cancers, even when advanced disease is controlled for.
Mainland patients from further away and island dwellers appear to
have shorter intervals between diagnosis and treatment compared
with those living closer to their cancer treatment centre. Despite
this, these groups had increased mortality.
Strengths and limitations of study. We were able to explore our
important research questions with greater definition than has
previously been possible. The data analysed and presented were
drawn from a comprehensive and detailed clinical data set. The
methods used to compile the data ensure that many of the fields
are automatically populated from quality electronic referral
systems, enabling a high degree of completeness and accuracy
(Brewster et al, 1994, 2002; Information Services Division, 2012).
This was a large population-based sample and data have been
included on those who died or did not otherwise receive treatment.
Our study had almost complete and accurate data on rurality,
deprivation and GIS calculations.
Our analysis is novel and innovative and based within a
geographically diverse region of Scotland including the full range
of sociodemographic and geographic concepts. Our approach and
findings should now be confirmed in other areas of the United
Kingdom and beyond.
A further strength is that, although we lacked complete and
detailed staging data, we were able to adjust for metastatic disease
at diagnosis, and conduct supplementary sensitivity analyses using
the staging data that we did have (Parks et al, 2004). We also
conducted a further supplementary sensitivity analysis where we
included neither stage nor presence of metastatic disease at
diagnosis. This is very important as it controls for the potential
impact of prolonged patient delay in remote and rural areas. We
can therefore reject the otherwise tempting and nihilistic conclu-
sion that our results simply reflect rural stoicism, with longer
delays and later-stage diagnoses in rural areas as a matter of course.
Instead, the results suggest that potentially malleable system factors
are in play and require to be urgently elucidated.
Some limitations to our data and analysis must be acknowledged.
The study was observational and retrospective, and dependent on the
quality of routinely collected data. Adjustment has been carried out, but
there will still be some residual confounding that could lead to either an
overestimation or underestimation of risk. In particular, this study did
not collect information on lifestyle factors or patient choices with regard
to treatment and care that may have potentially identified other
explainable reasons for mortality rates. It is possible that some of these
unmeasured confounders could explain or mask the observations.
Northeast Scotland and the Islands do not have the same high
levels of deprivation seen in some other areas of Scotland (e.g., the
central industrial belt of Scotland). There are, however, significant
pockets of deprivation and overall the area is less affluent than, for
example, parts of England and Wales. Deprivation scores are
collected at the level of the smallest area possible and this method
has previously been found sensitive enough to detect mortality
differences for common cancers in Scotland (Campbell et al, 2000).
Extension of the work to the whole of Scotland will encompass all
deprivation groups and this work is in development.
Analysis of travel time for those residing in the mainland region
are based on times travelled by private transport, whereas those on
island communities are for travel time by air from main island
airport to airport in the city where regional cancer centre is located
and time to travel by taxi to and from airports. We were unable to
control for actual travel time based on accessibility to car
ownership or reliability of public transport or hospital transport.
Public transport or ambulance transfers could potentially double
journey times. The GIS accounted for variation in road classifica-
tion but we were unable to reliably account for traffic volume, road
Table 1. Patient and pathway characteristics at the time of
referral
Variable N, total¼12339 %
Gender
Male 5422 43.9
Female 6917 56.1
Deprivation (quintiles based on SIMD)
SIMD Q1 (most) 608 4.9
SIMD Q2 1522 12.3
SIMD Q3 2878 23.3
SIMD Q4 3675 29.8
SIMD Q5 (least) 3656 29.6
Rurality (based on Scottish two-fold URC)
Urban 8071 65.4
Rural 4268 34.6
Urgency/referral status
Urgent suspected cancer
(USC)
3200 25.9
Urgent 2224 18.0
Routine 1414 11.5
Screening 1876 15.2
Emergency 1615 13.1
Other 2010 16.3
Cancer type
Breast 3772 30.6
Ovarian 324 2.6
Cervical 133 1.1
Prostate 2007 16.3
Melanoma 575 4.7
Lung 1736 14.1
Oesophagogastric 1017 8.2
Colorectal 2775 22.5
Charlson comorbidity index (excluding cancer and metastatic
cancer)
0 8537 69.2
1 2173 17.6
2 872 7.1
3 392 3.2
4 219 1.8
5 93 0.7
6þ 53 0.4
Charlson comorbidity index–condition
Acute MI 757 6.1
Cerebral vascular accident 493 4.0
Congestive heart failure 428 3.5
Connective tissue disorder 202 1.6
Dementia 129 1.0
Diabetes without long-term
complications
977 7.9
Mild or moderate liver disease 39 0.3
Peptic ulcer 289 2.3
Peripheral vascular disease 522 4.2
Pulmonary disease 1414 11.5
Diabetes with long-term
complications
77 0.6
Paraplegia 61 0.5
Renal disease 595 4.8
Severe liver disease 13 0.1
HIV o10 o0.1
Diagnostic procedure
Imaging 2104 17.1
Endoscopy/endoscopic
biopsy
5778 46.8
Operative biopsy/surgery 3870 31.4
Other 587 4.8
Main treatment type
Surgery 6298 51.0
Chemotherapy/radiotherapy 4948 40.1
Other 1093 8.9
Metastatic cancer
Yes 1357 11.0
No 10 982 89.0
Abbreviations: HIV¼ human immunodeficiency virus; MI¼myocardial infarction; SIMD¼
Scottish Index of Multiple Deprivation; URC¼urban rural classification.
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works and weather conditions that may affect travel times
disproportionately.
Our assessment of comorbidity was based on hospital admission
data that have previously been shown to compare well with case
note review (Soo et al, 2014). We must also acknowledge however
that patients with increasing burden of travel will have concurrent
comorbidities managed in primary care rather than be admitted to
hospital (Wallace et al, 2015). It is also possible that for diseases
such as diabetes there is wide variation in the completeness of
recording in hospital admission data (Anwar et al, 2011). The
combination of these factors could contribute to an under-
estimation of comorbidities in our patient population.
Access to health services depends on a wide range of factors
and we were unable to account for interactions between supply
and demand of services; for example, capacity of services and
qualified personnel available at the time of referral, diagnosis and
treatment.
Comparison with other studies. Previous research in the
early 2000s found that increasing distance from a cancer centre
was associated with less chance of diagnosis before death for rural
patients with stomach, breast and colorectal cancers, but there were
also contradictory findings showing evidence of shorter time to
treatment for women with breast cancer (Campbell et al, 2000;
Robertson et al, 2004). Our adjusted analyses found that between
2007 and 2013, people with cancer with an increased burden of
travel were treated more quickly irrespective of cancer site. It is
worth noting that previous research pre-dated the introduction of
the Scottish Referral Guidelines for Suspected Cancer, and hence it
Table 2. Patient outcomes and relationships of travelling time from home to GP, cancer diagnosis centre and cancer treatment
centre
Outcome¼ treatment within 62 days of GP referral
Travelling time (min) o5.0 5.0–9.9 10.0–14.9 415.0 Islands
Time from home to GP practice N 6439 3123 1069 792 916
N event (%) 4311 (67.0) 2019 (64.7) 681 (63.7) 510 (64.4) 633 (69.1)
Unadjusted OR (95% CI) 1.00 0.90 (0.83–0.99) 0.87 (0.76–0.99) 0.89 (0.77–1.04) 1.10 (0.95–1.28)
Adjusteda OR (95% CI) 1.00 0.89 (0.80–0.98) 0.85 (0.73–0.99) 0.84 (0.70–1.01) 1.02 (0.86–1.21)
Travelling time (min) o15.0 15.0–29.9 30.0–59.9 460.0 Islands
Time from home to cancer diagnosis centre N 5420 2313 2418 1272 916
N event (%) 3619 (66.8) 1540 (66.6) 1516 (62.7) 846 (66.5) 633 (69.1)
Unadjusted OR (95% CI) 1.00 0.99 (0.89–1.10) 0.84 (0.76–0.92) 0.99 (0.87–1.13) 1.11 (0.96–1.30)
Adjusteda OR (95% CI) 1.00 1.04 (0.93–1.17) 0.92 (0.81–1.04) 0.93 (0.80–1.08) 1.07 (0.90–1.28)
Time from home to cancer treatment centre N 4105 1764 2523 3031 916
N event (%) 2645 (64.4) 1174 (66.6) 1635 (64.8) 2067 (68.2) 633 (69.1)
Unadjusted OR (95% CI) 1.00 1.10 (0.98–1.24) 1.02 (0.92–1.13) 1.18 (1.07–1.31) 1.24 (1.06–1.44)
Adjusteda OR (95% CI) 1.00 1.08 (0.94–1.24) 1.12 (0.98–1.27) 1.42 (1.25–1.61) 1.32 (1.09–1.59)
Outcome¼ treatment within 31 days of diagnosis
Travelling time (min) o5.0 5.0–9.9 10.0–14.9 415.0 Islands
Time from home to GP practice N 6439 3123 1069 792 916
N event (%) 3532 (54.9) 1682 (53.9) 593 (55.5) 407 (51.4) 546 (59.6)
Unadjusted OR (95% CI) 1.00 0.96 (0.88–1.05) 1.03 (0.90–1.17) 0.87 (0.75–1.01) 1.22 (1.06–1.40)
Adjusteda OR (95% CI) 1.00 0.98 (0.89–1.07) 1.12 (0.97–1.29) 0.89 (0.75–1.05) 1.21 (1.03–1.41)
Travelling time (min) o15.0 15.0–29.9 30.0–59.9 460.0 Islands
Time from home to cancer diagnosis centre N 5420 2313 2418 1272 916
N event (%) 2909 (53.7) 1286 (55.6) 1323 (54.7) 696 (54.7) 546 (59.6)
Unadjusted OR (95% CI) 1.00 1.08 (0.98–1.19) 1.04 (0.95–1.15) 1.04 (0.95–1.15) 1.29 (1.11–1.47)
Adjusteda OR (95% CI) 1.00 1.06 (0.95–1.18) 0.99 (0.88–1.11) 0.90 (0.78–1.04) 1.20 (1.02–1.41)
Time from home to cancer treatment centre N 4105 1764 2523 3031 916
N event (%) 2192 (53.4) 964 (54.7) 1335 (52.9) 1723 (56.9) 546 (59.6)
Unadjusted OR (95% CI) 1.00 1.05 (0.94–1.18) 0.98 (0.89–1.08) 1.15 (1.05–1.26) 1.29 (1.11–1.49)
Adjusteda OR (95% CI) 1.00 1.10 (0.97–1.25) 1.01 (0.90–1.14) 1.20 (1.07–1.35) 1.33 (1.12–1.57)
Outcome¼diagnosis and treatment started on same or next day
Travelling time (min) o5.0 5.0–9.9 10.0–14.9 415.0 Islands
Time from home to GP practice N 6436 3120 1068 791 913
N event (%) 981 (15.2) 468 (15.0) 133 (12.5) 129 (16.3) 187 (20.5)
Unadjusted OR (95% CI) 1.00 0.98 (0.87–1.11) 0.79 (0.65–0.96) 1.08 (0.89–1.32) 1.43 (1.20–1.71)
Adjusteda OR (95% CI) 1.00 1.00 (0.79–1.27) 0.87 (0.59–1.30) 0.92 (0.60–1.42) 1.68 (1.14–2.47)
Travelling time (min) o15.0 15.0–29.9 30.0–59.9 460.0 Islands
Time from home to cancer diagnosis centre N 5418 2308 2417 1272 913
N event (%) 751 (13.9) 377 (16.3) 378 (15.6) 205 (16.1) 187 (20.5)
Unadjusted OR (95% CI) 1.00 1.21 (1.06–1.39) 1.15 (1.01–1.32) 1.19 (1.01–1.41) 1.60 (1.34–1.91)
Adjusteda OR (95% CI) 1.00 1.09 (0.91–1.31) 0.91 (0.75–1.11) 0.82 (0.65–1.04) 1.54 (1.19–1.98)
Time from home to cancer treatment centre N 4103.0 1759 2522 3031 913
N event (%) 575 (14.0) 271 (15.4) 378 (15.0) 487 (16.1) 187 (20.5)
Unadjusted OR (95% CI) 1.0 1.12 (0.96–1.31) 1.08 (0.94–1.25) 1.18 (1.03–1.34) 1.58 (1.32–1.90)
Adjusteda OR (95% CI) 1.0 1.12 (0.91–1.39) 0.97 (0.79–1.19) 1.16 (0.96–1.41) 1.72 (1.31–2.25)
Abbreviations: 95% CI¼ 95% confidence interval; GP¼general practitioner; OR¼odds ratio.
aAdjusted for age, gender, urban/rural code 2, deprivation, urgency/referral status, cancer type, procedure type, Charlson comorbidity index (CCI) score, treatment type and metastatic cancer.
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is possible that these have had a particular impact in rural areas of
the region (NHS Scotland, 2016).
In a study from a broadly analogous geographical region,
increased travel time to a GP was associated with more advanced
stage at diagnosis for breast and colorectal cancers and increased
risk of death for prostate cancer (Jones et al, 2008a). More recently,
evidence suggests that cancer services tend to be located farther
from areas with more cancer cases, and that longer travel times are
associated with worse survival (Murage et al, 2016). A study of all
country-specific cancer diagnoses for the period 1991–1995 found
that increasing distance from a cancer centre was associated with
less chance of diagnosis before death, a marker of more advanced
disease, for stomach, breast and colorectal cancers and poorer
survival after diagnosis for prostate and lung cancers (Campbell
et al, 2000). It is important to note, therefore, that the paradoxical
findings in our study have remained following our adjustments for
more advanced disease.
Previous studies have also explored the possibility that increased
distance from health services affects the type of treatment received.
Those living further away from cancer centres are less likely to
receive surgery and/or receive chemotherapy or radiotherapy
(Campbell et al, 2002; Jones et al, 2008b; Lin et al, 2015). Patients
who were 41 h from a hospital had lower admission rates to a
specialist cancer centre (Baird et al, 2008), suggesting that patients
may not want to spend much time travelling to hospital.
‘Distance bias’ however has also been attributed to more
favourable outcomes. Patients who travel X50 miles to their
treating hospital are reported to be more likely to have surgery at
high-volume hospitals (Gunderson et al, 2013), concluding that
patients who visit hospital from a long distance may wish for more
aggressive treatment. In other studies, greater travel distance was
positively associated with receipt of therapy (Massarweh et al,
2014), and greater travel times to hospital were associated with
better chances of survival for breast and lung cancers (Jones et al,
2008a). It is important to note that we adjusted for treatment type
in our analyses and suggest that differential treatment cannot be
the sole explanation of poorer cancer outcomes for those with an
increased burden of travel.
Studies have also shown no evidence for an association between
distance or travel time from health facilities in relation to health
outcomes. Later-stage breast cancer was not associated with travel
time to the nearest mammography facility (Celaya et al, 2010) and
travel time had no effect on stage of colorectal cancer at diagnosis
or receipt of treatment (Crawford et al, 2012).
Possible explanations, implications and further research. The
contradictory findings on time to diagnosis and mortality are
perplexing. The fact that we have controlled for the presence of
metastatic disease at diagnosis limits the possibility that our results
simply reflect later-stage presentation by people who live further
from key healthcare facilities. The findings suggest that what
happens to patients subsequent to their diagnosis may be much
more important. Residing in areas with increasing burden of travel
might limit treatment choices once a diagnosis has been made.
Faced with two treatment options, patients might weigh the costs
in terms of time, expense and inconvenience of travel against the
perceived benefits, for example, choosing surgery over chemother-
apy to limit time in hospital (Greenberg et al, 1998). Lengthy or
difficult travel to a cancer centre or hospital could also limit
engagement with post-primary treatment follow-up, with conse-
quent implications for the effective management of treatment
effects and the identification of other follow-up needs. Further
research is essential to understand the true interplay of these and
other factors.
For the first time we have sought differences between burden of
travel and the cancer care pathway for both island and mainland
communities. We investigated whether patients from an island
community were more likely to have their diagnosis and begin
treatment on the same or next day and found evidence that this
was so. In addition, many island patients in the region benefit from
subsidised air travel and accommodation that potentially could
encourage greater engagement with follow-up than their mainland
counterparts with increasing burden of travels. Our findings
suggest, however, that even these additive advantages during the
early stages of the cancer pathway do not translate to equitable
outcomes with people living closer to their cancer treatment centre.
Finally, it is important to consider that our results could also
reflect some successes. Rural and remote populations have been the
focus of improved quality of care for several years. The quicker
time to treatment observed here could wholly or partly result from
targeted interventions, for example, mobile screening units and
public awareness campaigns. It is possible that our findings actually
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Figure 2. Survival curve according to travelling time to cancer
treatment centre from place of residence.
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Figure 3. Cancer-specific survival curve according to travelling time to
cancer treatment centre from place of residence.
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reflect greater geographical equity than would have been the case at
earlier periods in recent history.
Future researchers should confirm these findings in the wider
United Kingdom and beyond, but the key challenge now is to
elucidate the mechanisms underpinning the observed paradoxical
relationship between burden of travel, process of care and cancer
outcomes. We recommend further mixed methods studies using
our approach to data linkage and supplemented by qualitative
research to fully understand how cancer services can be best
configured to suit the needs of diverse populations.
CONCLUSIONS
Island dwellers and mainland residents with 460min of journey
to their cancer treatment centre are diagnosed more quickly and
are more likely to receive treatment within the recommended time
even after important confounders have been controlled for. This
does not however translate into reduced mortality at 1 year
following GP referral. Our results are somewhat unexpected and
paradoxical. The effects remain even when we control for the most
obvious explanation, more advanced disease in patients with
increased burden of travels.
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